Home › Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline
 

Keywords :   


Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline

2014-02-05 07:22:08| drugdiscoveryonline News Articles

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced its key “Alnylam 5x15” pipeline goals. The company also announced today that it now expects to exceed its original “Alnylam 5x15” guidance from 2011, where Alnylam had guided to have five genetic medicine programs in the clinic by the end of 2015

Tags: key goals pipeline therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »